The MR sensitivity analyses did not provide strong evidence of heterogeneity or pleiotropy for the effect of SGLT2 inhibition on prostate cancer, but the statistical power to clearly demonstrate this was low (Tables S6 and S7). This evidence concerns the gene SLC5A2 and prostate cancer.